Friday, January 23, 2026

Latest

Medipharm Labs Appoints Former Purdue Pharma Exec As CEO

Medipharm Labs (TSX: LABS) continues to suffer from management turnover. The company today announced that its CEO, Bryan Howcroft, will be stepping down for personal reasons effective immediately. Howcroft was in the role for just six months.

Taking Howcroft’s place within the company is that of David Piddick, whom Medipharm lists as previously serving as a president and CEO of a “Canadian pharmaceutical company.” That pharma company is believed to be Purdue Pharma Canada, whom notably faced numerous lawsuits related to the opioid pandemic which ultimately lead to a bankruptcy filing in the US. Piddick will also serve on the firms board of directors.

Piddick reportedly has over two decades worth of senior leadership experience within the healthcare industry. He currently holds a MBA from Northwestern University.

“In MediPharm, I see one of the very few organizations globally that has the required sophistication to both operate within a stringent Pharma environment, and scale rapidly to capitalize on this growth opportunity. I look forward to contributing my experience in business and corporate development to the team’s current efforts, with a focus on orienting the Company toward both consistent organic growth and accretive M&A activities to drive revenue growth, profitability and value for all stakeholders,” commented Piddick on his appointment.

As part of Piddick’s compensation package, he was issued 14.8 million RSU’s in connection with his appointment, as well as 5.2 million stock options.

Howcroft meanwhile has exited his role from the firm entirely, announcing this morning he will also be vacating his position on the firms board.

Medipharm Labs last traded at $0.145 on the TSX.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

2 Responses

Video Articles

Moon River Moly: The Davidson Moly-Copper-Tungsten PEA

Integra: The DeLamar Heap Leach Feasibility Study

Highlander Silver: The Saviour Of Bear Creek Mining

Recommended

Steadright Subsidiary NSM Capital Sarl Applies For License At Titanbeach One

Goliath Resources Accelerates Option Agreement On Golddigger While Reducing NSR

Related News

Medipharm Labs Ships First Topical Products

Medipharm Labs (TSX: LABS) is now in the cannabis topicals business. The company announced this...

Wednesday, March 25, 2020, 08:20:53 AM

MediPharm Labs, Vivo Cannabis Slump After Announcing All-Stock Deal

MediPharm Labs (TSX: LABS) announced on Thursday an all-equity deal to acquire VIVO Cannabis (TSX:...

Sunday, December 25, 2022, 01:35:00 PM

MediPharm Labs Revenues Continue To Decline, Posts Negative Gross Margin

Medipharm Labs (TSX: LABS) this morning continued to show its desperate need for effective leadership....

Monday, August 16, 2021, 08:52:05 AM

Medipharm Announces White Label Agreement With Argentia Gold

Medipharm Labs (TSX: LABS) and Argentia Gold Corp this morning jointly announced a supply agreement,...

Wednesday, May 27, 2020, 08:34:11 AM

Medipharm Labs Sees PI Financial, Mackie Research Drop Estimates, Price Targets

Medipharm Labs (TSX: LABS) reported Q1 2020 results on Thursday, June 18, which showed it’s...

Friday, June 19, 2020, 02:55:31 PM